Similar articles for PMID: 27279341

Year	Number of Results
2005	6
2006	4
2007	5
2008	1
2009	3
2010	17
2011	23
2012	16
2013	24
2014	19
2015	21
2016	15
2017	14
2018	20
2019	10
2020	15
2021	8
2022	15
2023	5
2024	0

1

Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis.

Rogliani P, Calzetta L, Cazzola M, Matera MG. Rogliani P, et al. Expert Opin Drug Saf. 2016 Aug;15(8):1133-46. doi: 10.1080/14740338.2016.1199683. Epub 2016 Jun 20. Expert Opin Drug Saf. 2016. PMID: 27279341 Review.

2

Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.

Rennard SI, Calverley PM, Goehring UM, Bredenbröker D, Martinez FJ. Rennard SI, et al. Respir Res. 2011 Jan 27;12(1):18. doi: 10.1186/1465-9921-12-18. Respir Res. 2011. PMID: 21272339 Free PMC article.

3

Roflumilast added to triple therapy in patients with severe COPD: a real life study.

Muñoz-Esquerre M, Diez-Ferrer M, Montón C, Pomares X, López-Sánchez M, Huertas D, Manresa F, Dorca J, Santos S. Muñoz-Esquerre M, et al. Pulm Pharmacol Ther. 2015 Feb;30:16-21. doi: 10.1016/j.pupt.2014.10.002. Epub 2014 Oct 30. Pulm Pharmacol Ther. 2015. PMID: 25445930

4

Roflumilast for severe COPD?

[No authors listed] [No authors listed] Drug Ther Bull. 2011 Apr;49(4):45-8; quiz iii-iv. doi: 10.1136/dtb.2011.02.0025. Drug Ther Bull. 2011. PMID: 21467576 Review.

5

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.

Chong J, Leung B, Poole P. Chong J, et al. Cochrane Database Syst Rev. 2017 Sep 19;9(9):CD002309. doi: 10.1002/14651858.CD002309.pub5. Cochrane Database Syst Rev. 2017. PMID: 28922692 Free PMC article. Updated. Review.

6

Roflumilast (Daliresp) for COPD.

[No authors listed] [No authors listed] Med Lett Drugs Ther. 2011 Jul 25;53(1369):59-60. Med Lett Drugs Ther. 2011. PMID: 21778965 No abstract available.

7

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.

Chong J, Leung B, Poole P. Chong J, et al. Cochrane Database Syst Rev. 2013 Nov 4;(11):CD002309. doi: 10.1002/14651858.CD002309.pub4. Cochrane Database Syst Rev. 2013. PMID: 24190161 Updated. Review.

8

Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.

Pinner NA, Hamilton LA, Hughes A. Pinner NA, et al. Clin Ther. 2012 Jan;34(1):56-66. doi: 10.1016/j.clinthera.2011.12.008. Clin Ther. 2012. PMID: 22284994 Review.

9

Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial.

Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Martinez FJ, et al. Lancet. 2015 Mar 7;385(9971):857-66. doi: 10.1016/S0140-6736(14)62410-7. Epub 2015 Feb 13. Lancet. 2015. PMID: 25684586 Clinical Trial.

10

Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Oba Y, Lone NA. Oba Y, et al. Ther Adv Respir Dis. 2013 Feb;7(1):13-24. doi: 10.1177/1753465812466167. Epub 2012 Nov 29. Ther Adv Respir Dis. 2013. PMID: 23197074 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

213 results

Results by year